EBV Early Antigen, Diffuse Only

  • Applications
    • IF
  • Code # EAD-5412
  • Size 12 wells
  • Price Call for Price


The Epstein-Barr Virus (EBV) was first detected and described by Epstein, Barr and Achong in electron-microscopic studies of lymphoblastoid cultures obtained from patients with Burkitt’s Lymphoma.The etiologic role of EBV in Infectious Mononucleosis (IM) was first reported in 1968 and has since been well documented to be the causative agent. Infection with EBV results in the expression of several viral proteins to which the host responds with appropriate antibodies.

  • Application:
  • Components:

    MBL Bion EPSTEIN-BARR EARLY ANTIGEN (DIFFUSE) SUBSTRATE SLIDES are individually foil-wrapped twelve well slides with a mixture of lymphocytic cells (Raji) that have been infected with Epstein-Barr Virus (P3HR-1 strain) fixed onto each well. Each well contains an average of 10-20% infected cells per 200X field.

  • Description:

    The MBL Bion EPSTEIN-BARR EARLY ANTIGEN (DIFFUSE) ANTIGEN SUBSTRATE SLIDES may be utilized in the indirect fluorescent antibody assay method. Each lot is tested with a panel of titered sera to ensure sensitivity lot to lot; both positive and negative cells are in each well to provide a built-in control.

    For Research Use Only

  • Product Type:
    Antigen Substrate Slide
  • Research Area:
    Infectious Disease
  • Short Description:
    For Research Use Only. Not for use in diagnostic procedure.
  • Size:
    12 wells
  1. Epstein, M.A., B.G. Achong, Y.M. Barr, Virus Particles in Cultured Lymphoblasts from Burkitt’s Lymphoma, Lancet, 1:702-703, 1964.
  2. Epstein, M.A., Y.M. Barr, B.G. Achong, Studies with Burkitt’s Lymphoma, Wistar Inst. Sympos. Monogr., 4:69-82, 1965.
  3. Henle, G., W. Henle, V. Diehl, Relation of Burkitt’s Tumor-Associated Herpes-type Virus to Infectious Mononucleosis, Proc. Nat. Acad. Sci., 59:94-101, 1968.
  4. Henle, W., G. Henle, Epstein-Barr Virus: The Cause of Infectious Mononucleosis, A Review in: Oncogenesis and Herpesviruses, Biggs, I.M., G. de The, L.N. Payne (eds), IARC, Sci. Publ. No.2, Lyon, 269-274, 1972.
  5. Miller, D., Epstein-Barr Herpes Virus and IM, Prog. Med. Virol., 20:84-112, 1975.
  6. Henle, W., G. Henle, C.A. Horwitz, Epstein-Barr Virus Specific Diagnostic Tests in Infectious Mononucleosis, Human Path., 5:551-564, 1974.
  7. Henle, W., G. Henle, Epstein-Barr Virus-Related Serology in Hodgkin’s Disease, Natl. Cancer Inst. Monogr., 36:79-84, 1973.
  8. Evans, A.S., The Spectrum of Infections with EB Virus: A Hypothesis, J. Infect. Dis., 124:330-335, 1971.
  9. Takada, M., et al., The Establishment of Cultured Cell Lines from the Patients with Izumi Fever and Infectious Mononucleosis Like Diseases, Japan J. Exp. Med., 43:209-214, 1973.
  10. Lennette, E.T., Diagnosis of Epstein-Barr Virus Infections, in: Laboratory Diagnosis of Viral Infections, Lennette, E.H. (ed), Marcel Dekker, New York, 1985.
  11. Henle, G., W. Henle, The Diagnosis of Epstein-Barr Virus Infections, in: The Human Herpesviruses, Nahamias, A.J., W.R. Dowdle, R.F. Schinazi (eds), Elsevier, New York, 374-378, 1981.
  12. Weller, T.H., A.H. Coons, Fluorescent Antibody Studies with Agents of Varicella and Herpes Zoster Propagated In Vitro, Proc. Soc. Exp. Biol. Med., 86:789-794, 1954.
  13. Riggs, J.L., R.J. Seiwald, J.H. Burckhalter, C.M. Downs, T.G. Metcalf, Isothiocyanate Compounds as Fluorescent Labeling Agents for Immune Serum, Am. J. Pathol., 34:1081-1097, 1958.
  14. Goldman, M., Fluorescent Antibody Methods. New York, Academic Press, 1968.
  15. Kawamura, A. Jr., Fluorescent Antibody Techniques and Their Application. Baltimore, University Park Press, 1969.
  16. Nairn, R.C., Fluorescent Protein Tracing, Baltimore, Williams and Wilkins, 3rd Ed., 1969.
  17. Johnson, R.B., and R. Libby, Separation of Immunoglobulin M (IgM) Essentially Free of IgG From Serum in Systems Requiring Assay of IgM-Type Antibodies Without Interference From Rheumatoid Factor, J. Clin. Micro. 12:451-454, 1980.
  18. Gispen, R., J. Nagel, B. Brand-Saathof, S. DeGraff, Immunofluorescence Test for IgM Rubella Antibodies in Whole Serum After Absorption with Specific Anti-gamma Fc, Clin. Exp. Immunol., 2:431- 437, 1975.
  19. Joassin, L., M. Reginster, Elimination of Nonspecific Cytomegalovirus Immunoglobulin M Activities in the Enzyme-Linked Immunosorbent Assay by Using Antihuman Immunoglobulin G, J. Clin. Microbiol. 23:576-581, 1986.
  20. Lyerla, H.C., F.T. Forrester, The Immunofluorescence (IF) Test, in: Immunofluorescence Methods in Virology, USDHHS, Georgia, 71-81, 1979.
  21. Holborow, E.J., D.M. Weir, G.D. Johnson, A Serum Factor in Lupus Erythematosus With Affinity for Tissue Nuclei, Br. Med. J., 11:732-734, 1957. 22.
  22. Berg, P.A., I. Roitt, D. Doniach, H.M. Cooper, Mitochondrial Antibodies in Primary Biliary Cirrhosis, Immunol. 17:281-293, 1969.
  23. Schmitz, H. and M. Scherer, IgM Antibodies to Epstein-Barr Virus in Infectious Mononucleosis, Arch, Gesmt Virusforsch, 37:332-339, 1972.
  24. McCormack, J.G., E. Nowakowski, B.B. Fernandez, The Place of Epstein-Barr Virus Testing in a Clinical Laboratory, Lab. Med., Vol. 8 No. 8:12-15, 1977.
  25. Smith, T., Director, Dept. of Virology, Sect of Clinical Micro, Mayo Clinic, Personal Communication.
  26. Goldman, J.M., M.L. Goodman, D. Miller, Antibody to EB Virus in American Patients with Carcinoma of the Nasopharynx, J.A.M.A., 216:1618-1622, 1971.
  27. Chernesky, M.A., C.G. Ray, T.F. Smith, Laboratory Diagnosis of Viral Infections, Cumitech 15, ASM, Washington, D.C., March 1982.
  28. Schmidt, N.J., Update on Class-specific Viral Antibody Assays, Clinical Immunology Newsletter, 5 (6) : 81-85, June, 1984.
  29. Gardner, P.S., J. McQuillin, Rapid Virus Diagnosis: Application of Immunofluorescence, In: Detection of Virus Specific IgM by Immunofluorescence, Butterworth, Boston, 259-287, 1980.
  30. Ascher, M., Supr, Immunol/Virol Lab, Elmhurst Mem Hosp, Elmhurst, IL, Personal Communication.
  31. Paxton, H., Dir, Immuno, Maryland Medical Lab, Baltimore, MD., Personal Communication.
  32. Forsgren, M. and A. Demissie, IgM Responses to EBV/CMV in Cytomegalovirus and Epstein-Barr Infections in: The Human Herpesviruses, A.J. Nahmias, W.R. Dowdle, and R.F. Schinazi, (eds), Elseiver, New York:662, 1981.
  33. Neiderman, J.C., et al., Infectious Mononucleosis: Clinical Manifestations in Relation to EB VirusAntibodies, J.A.M.A. 203:205-209, 1968.
  34. Nickoskelainen, J., P. Hanninen, Antibody Response to Epstein-Barr Virus in Infectious
  35. Sutton, R.N.P., The Diagnosis of Infections with the Epstein-Barr Virus. J. Infect. 1:301-322, 1979.
  36. Tischendorf, P., et al., Development and Persistence of Immunity to Epstein-Barr Virus in Man, J. of Infect. Dis., 122:401-409, 1970.
  37. Data on file, MBL Bion, Des Plaines, Illinois.
  38. Landry, M.L. and G.D. Hsiung, Diagnosis of Dual Herpes Virus Infection: Varicella Zoster and Herpes Simplex Virus in: The Human Herpesviruses,A.J. Nahmias, W.R. Dowdle, and R.F. Schinazi, Elseiver, New York:652-653, 1981.
  39. Joncas, J., et.al., Dual Congenital Infection with the Epstein-Barr Viruses (EBV) and the Cytomegalovirus (CMV) in: The Human Herpesviruses, A.J. Nahmias, W.R. Dowdle, and R.F. Schinazi, (eds), Elseiver, New York:614, 1981.
  40. Rossier, E., H.R. Miller, P.H. Phipps, Rapid Viral Diagnosis by Immunofluorescence, An Atlas and Practical Guide, Univ. of Ottawa Press, Ottawa, 127-137, 1989.
  41. Ho, M., Cytomegalovirus, Biology and Infection, Plenum, New York, pp44, 133, 169, 1982